Using directed evolution and structure-guided design, human synthetic antibodies selective to HER2 point mutants were developed. The use of the antibodies as T cell engagers killed HER2-mutant cancer cells while sparing HER2-wild-type normal cells.
- Injin Bang
- Takamitsu Hattori
- Shohei Koide
